Brickell starts pivotal Phase III trial of drug candidate in U.S. – Longmont Times-Call

Brickell Biotech Inc. (Nasdaq: BBI) has kicked off its final clinical trial in the U.S. for its anti-underarm sweating treatment.
In a statement, the Boulder company said it would start recruiting up to 350 subjects for its tests of Sofpironium Bromide for an eight-week period, but did not set a…

Continue Reading

You might also like